Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Groupama Asset Managment

Groupama Asset Managment lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 155.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,416 shares of the medical research company's stock after acquiring an additional 2,079 shares during the period. Groupama Asset Managment's holdings in Charles River Laboratories International were worth $627,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of CRL. Virtu Financial LLC acquired a new position in Charles River Laboratories International during the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. State Street Corp raised its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International in the third quarter valued at approximately $966,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CRL shares. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 18th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $190.00 to $170.00 in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $189.77.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $3.70 during midday trading on Monday, hitting $133.20. The stock had a trading volume of 798,162 shares, compared to its average volume of 771,718. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $162.49 and a 200-day simple moving average of $180.59. The company has a market capitalization of $6.81 billion, a PE ratio of 883.29, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $128.09 and a 1 year high of $258.56.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).